HEMGENIX - AN OVERVIEW

Variety of qualified clients: CDEC talked about the uncertainty in the number of individuals with moderately critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or reasonable illness might have a e